Mental health represents a significant global healthcare opportunity, with more than 1 billion people globally1 living with a mental disorder and depression and anxiety alone estimated to cost the global economy approximately $1 trillion annually2. Sarborg has developed a proprietary database of neuropsychiatric disease signatures, including depression, bipolar disorder, anxiety and schizophrenia, and has successfully applied its Signature Intelligence and quantum computing models to identify potential relationships between disease signatures and therapeutic candidates.

CDT believes the application of Sarborg’s technology to neuropsychiatric drug discovery demonstrates the broader potential of its patented models across significant areas of unmet medical need. Sarborg is currently in discussions with pharmaceutical and biotechnology companies, academic institutions and research organisations regarding potential applications and strategic collaborations.

"We are pleased to see Sarborg successfully applying its patented Signature Intelligence and quantum computing models to the mental health sector," said James Bligh, Chief Executive Officer of CDT Equity. "The ability to combine proprietary biological signatures with quantum computing has the potential to uncover new relationships and therapeutic opportunities within highly complex disease areas."

CDT holds 1,290 shares in Sarborg, representing 22.7% of the issued share capital. Sarborg’s latest capital raise was at $125,000 per share, implying a fully diluted valuation of approximately $709 million.